Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP331549.RA-PAHJg0M2p2mW5x2zWSfbVpH_KT4VmOUYwVwgCsasSM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP331549.RA-PAHJg0M2p2mW5x2zWSfbVpH_KT4VmOUYwVwgCsasSM130_assertion type Assertion NP331549.RA-PAHJg0M2p2mW5x2zWSfbVpH_KT4VmOUYwVwgCsasSM130_head.
- NP331549.RA-PAHJg0M2p2mW5x2zWSfbVpH_KT4VmOUYwVwgCsasSM130_assertion description "[To determine the feasibility of gene therapy for acquired immunodeficiency syndrome in individuals already infected with HIV-1, granulocyte colony-stimulating factor mobilized peripheral blood CD34+ cells were isolated from HIV-1-infected individuals and transduced with retroviral vectors containing three different anti-HIV-1-genes: the Rev binding domain of the Rev Responsive Element (RRE decoy) (L-RRE-neo), a double hammerhead ribozyme vector targeted to cleave the tat and rev transcripts (L-TR/TAT-neo), and the trans-dominant mutant of rev (M10) (L-M10-SN).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP331549.RA-PAHJg0M2p2mW5x2zWSfbVpH_KT4VmOUYwVwgCsasSM130_provenance.
- NP331549.RA-PAHJg0M2p2mW5x2zWSfbVpH_KT4VmOUYwVwgCsasSM130_assertion evidence source_evidence_literature NP331549.RA-PAHJg0M2p2mW5x2zWSfbVpH_KT4VmOUYwVwgCsasSM130_provenance.
- NP331549.RA-PAHJg0M2p2mW5x2zWSfbVpH_KT4VmOUYwVwgCsasSM130_assertion SIO_000772 9116267 NP331549.RA-PAHJg0M2p2mW5x2zWSfbVpH_KT4VmOUYwVwgCsasSM130_provenance.
- NP331549.RA-PAHJg0M2p2mW5x2zWSfbVpH_KT4VmOUYwVwgCsasSM130_assertion wasDerivedFrom befree-20150227 NP331549.RA-PAHJg0M2p2mW5x2zWSfbVpH_KT4VmOUYwVwgCsasSM130_provenance.
- NP331549.RA-PAHJg0M2p2mW5x2zWSfbVpH_KT4VmOUYwVwgCsasSM130_assertion wasGeneratedBy ECO_0000203 NP331549.RA-PAHJg0M2p2mW5x2zWSfbVpH_KT4VmOUYwVwgCsasSM130_provenance.